Skip to main
GENB

GENB Stock Forecast & Price Target

GENB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Generate Biomedicines is poised for success due to its innovative generative biology platform and strong pipeline of potential therapies for respiratory and infectious diseases. The partnerships and strong IP strategy provide a solid foundation for future growth. However, investors should be aware of potential risks such as delays in clinical trials and regulatory hurdles. The company's goal to achieve profitability by 2031 is a positive indicator of its long-term viability and potential for financial success.

Bears say

Generate Biomedicines is a clinical-stage biotechnology company with a focus on generative biology and AI-driven drug discovery and development. Despite the promising preclinical and clinical data for its lead asset GB-0895, which has a potential functional advantage compared to other biologics in the market, the stock has underperformed and is currently trading below its IPO price. This can be attributed to multiple factors, including investor fatigue with unvalidated platform claims in the biotech sector, potential manufacturing dependencies, and a competitive landscape in asthma and COPD treatment. Additionally, the company's limited cash position and potential need for additional funding could also pose risks to its future success.

GENB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generate Biomedicines Inc (GENB) Forecast

Analysts have given GENB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GENB has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generate Biomedicines Inc (GENB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.